PRNewsWire
27 Sept 2026, 03:16 UTC · 9h ago
Verdict
Headline takes no side. Three claims average +0.60 — strongly bullish.
+0.60strongly bullish
More positive than 93% of claims this week
Scored by the NIS engine · methodology.
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
FUCASO achieved a 95.9% objective response rate and a 94.1% MRD negativity rate in a real-world study of 281 heavily pretreated patients.
Newpress release dated Sep 26, 2026
So whatValidation of pivotal trial data in real-world settings typically accelerates payer reimbursement and market penetration within the next 6-12 months.
More positive than 99% of claims this week
Continue reading
5 related stories
Top 2 movers · tap to explore
The 12-month progression-free survival (PFS) rate for FUCASO was 71.5% and the overall survival (OS) rate was 87.8%.
Newpress release dated Sep 26, 2026
So whatWith median PFS/OS not yet reached at 10.97 months follow-up, current revenue estimates may understate the drug's long-term patient retention.
More positive than 93% of claims this week
Severe cytokine release syndrome (grade ≥3 CRS) occurred in only 3.8% of the study population.
Newpress release dated Sep 26, 2026
More positive than 78% of claims this week
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
16h ago
